Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-20, Stock:NVS, The news for the past five days is as follows:
2018-07-13: NEWS1: Novartis Looks to Exit Antibacterial, Antiviral Program.NEWS2: Novartis Looks to Exit Antibacterial, Antiviral Program.NEWS3: [$$] Novartis Communicated With Trump's Lawyer for Months, Report Says.NEWS4: Novartis Looks to Exit Antibacterial, Antiviral Program.NEWS5: Dems: Novartis deal with Cohen sought access to policymakers.NEWS6: Report: Ex-Trump lawyer often in touch with drug firm execs.NEWS7: Novartis Account of Cohen Connection Assailed by U.S. Senators.NEWS8: Rebound Lifts NASDAQ to New All-Time High.NEWS9: Rebound Lifts NASDAQ to New All-Time High.NEWS10: JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?.NEWS11: JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?.NEWS12: Better Know Biotech: Regenxbio Inc..NEWS13: Better Know Biotech: Regenxbio Inc..NEWS14: AT&T failed to provide requested documents to Senate probe of payments made to Michael Cohen.NEWS15: Novartis disputes U.S. senators' report on Cohen contract.NEWS16: JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?.NEWS17: Cohen Pitched Novartis Russia-Tied Investment, Democrats Say.NEWS18: Cohen's Novartis Work Was Broader Than Reported, Democrats Say.NEWS19: The Swiss Stock Market Finished With Modest Gains.NEWS20: The Swiss Stock Market Finished With Modest Gains.NEWS21: Better Know Biotech: Regenxbio Inc..NEWS22: Superbugs Win Another Round as Big Pharma Leaves Antibiotics.NEWS23: [$$] Democrats allege Trump lawyer had broad contacts with Novartis.NEWS24: [$$] Democrats allege broad Novartis contacts with Trump lawyer.
2018-07-16: NEWS1: Novartis’s Q2 2018 Estimates: Innovative Medicines Business.NEWS2: Segment-Wise Expectations for Novartis in Q2 2018.NEWS3: Expectations from Novartis’s Q2 2018 Earnings.NEWS4: The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft.NEWS5: The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft.NEWS6: Is a Surprise in the Cards for Novartis in Q2 Earnings?.NEWS7: Is a Surprise in the Cards for Novartis in Q2 Earnings?.NEWS8: FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%.NEWS9: Is a Surprise in the Cards for Novartis in Q2 Earnings?.NEWS10: The Swiss Stock Market Finished Slightly Lower In Choppy Trade.NEWS11: The Swiss Stock Market Finished Slightly Lower In Choppy Trade.NEWS12: The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft.NEWS13: Novartis had ‘longer and more detailed’ relationship with Trump lawyer Michael Cohen, Senate report finds.NEWS14: This Week's Biotech IPOs.NEWS15: This Week's Biotech IPOs.
2018-07-17: NEWS1: GlaxoSmithKline Is More Than Just a 5% Dividend Income Play.NEWS2: GlaxoSmithKline Is More Than Just a 5% Dividend Income Play.NEWS3: Pre-Market Earnings Report for July 18, 2018 :  ABT, MS, ASML, USB, NVS, MTB, NTRS, ERIC, TXT, GWW, MTG, UBSH.NEWS4: Pre-Market Earnings Report for July 18, 2018 :  ABT, MS, ASML, USB, NVS, MTB, NTRS, ERIC, TXT, GWW, MTG, UBSH.NEWS5: Earnings Outlook For Novartis.NEWS6: GlaxoSmithKline Is More Than Just a 5% Dividend Income Play.NEWS7: Roche's Flu Drug Meets Primary Endpoint in Phase III Study.NEWS8: Roche's Flu Drug Meets Primary Endpoint in Phase III Study.NEWS9: Novartis’s Q2 2018 Estimates: Alcon.NEWS10: The Swiss Stock Market Pulled Back As Heavyweights Fall.NEWS11: The Swiss Stock Market Pulled Back As Heavyweights Fall.NEWS12: Novartis’s Q2 2018 Estimates: Sandoz.
2018-07-18: NEWS1: Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto.NEWS2: Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto.NEWS3: FDA Oks Novartis' Kisqali For Use In Pre/Perimenopausal Women With Breast Cancer.NEWS4: FDA Oks Novartis' Kisqali For Use In Pre/Perimenopausal Women With Breast Cancer.NEWS5: Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto.NEWS6: Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript.NEWS7: Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript.NEWS8: 5 Big Biotech Stories to Watch.NEWS9: Novartis hints at 2018 outlook hike despite drug price freeze.NEWS10: Morgan Stanley gains on earnings; Novartis halts drug price hikes; Texas Instruments CEO steps down; Ford recalls 550K vehicles.NEWS11: Novartis Earnings: 'A Focused Company Wins,' Says CEO.NEWS12: Novartis Halts Drug Prices Hike In US.NEWS13: Novartis Halts Drug Prices Hike In US.NEWS14: Novartis’s Business Segments in Q2 2018.NEWS15: Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript.NEWS16: European ADRs Move Higher in Wednesday Trading.NEWS17: European ADRs Move Higher in Wednesday Trading.NEWS18: [$$] Novartis Won't Raise U.S. Drug Prices This Year.NEWS19: Novartis Reports Growth in Q2 2018 Earnings.NEWS20: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares.NEWS21: [$$] Novartis to Refrain From Raising U.S. Drug Prices.NEWS22: The Swiss Stock Market Rebounded On Pharma Strength.NEWS23: The Swiss Stock Market Rebounded On Pharma Strength.NEWS24: European Markets Climbed On Euro Weakness.NEWS25: European Markets Climbed On Euro Weakness.NEWS26: Novartis joins Pfizer in halting U.S. drug price hikes.NEWS27: Novartis: 2Q Earnings Snapshot.NEWS28: Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases.NEWS29: Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases.NEWS30: Novartis puts brakes on price hikes, bowing to U.S. pressure.NEWS31: Novartis puts brakes on price hikes, bowing to U.S. pressure.NEWS32: Swiss drugs giant Novartis says profit up as spinoff looms.NEWS33: Novartis Joins Pfizer in Holding Line on Drug Prices in U.S..NEWS34: Novartis Follows Pfizer in Holding Line on U.S. Prices.NEWS35: Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year.NEWS36: [$$] Novartis Confirms Outlook.NEWS37: [$$] Novartis Backs 2018 Outlook After Sales Grow.NEWS38: European Shares Advance On Growth Optimism.NEWS39: European Shares Advance On Growth Optimism.NEWS40: Novartis Blockbuster Drug Rebounds, Easing Generics Pressure.NEWS41: Novartis Stock Up As Q2 Results Top View, Backs FY18 Outlook.NEWS42: Novartis Stock Up As Q2 Results Top View, Backs FY18 Outlook.NEWS43: Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch.NEWS44: Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch.NEWS45: [$$] Chinese Hit Movie ‘Dying to Survive’ Injects Urgency in Drug-Price Push.NEWS46: Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch.NEWS47: Novartis Q2 Profit Surges; Reiterates FY18 Outlook - Quick Facts.NEWS48: Novartis Q2 Profit Surges; Reiterates FY18 Outlook - Quick Facts.
2018-07-19: NEWS1: Novartis won’t raise drug prices in US.NEWS2: Novartis&apos; (NVS) Kisqali Gets FDA Nod for Label Expansion.NEWS3: Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS.NEWS4: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut.NEWS5: [$$] Novartis, MorphoSys and Galapagos Shares Rise on Drug Deal.NEWS6: The Swiss Stock Market Slipped Into The Red Going Into The Close.NEWS7: The Swiss Stock Market Slipped Into The Red Going Into The Close.NEWS8: European Markets Finished Mixed In Lackluster Trade.NEWS9: European Markets Finished Mixed In Lackluster Trade.NEWS10: Trump thanks Novartis, Pfizer for not raising drug prices.NEWS11: Novartis to Pay as Much as $1 Billion for Rights to Skin Drug.NEWS12: Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug.NEWS13: European Shares Slide On Mixed Earnings.NEWS14: European Shares Slide On Mixed Earnings.NEWS15: Novartis Buys Exclusive Rights To IL-17C Compound MOR106 For Atopic Dermatitis.NEWS16: Novartis Buys Exclusive Rights To IL-17C Compound MOR106 For Atopic Dermatitis.NEWS17: [$$] Novartis Won’t Raise U.S. Drug Prices This Year.

Answer: Rise